Familial adenomatous polyposis
Conditions
Interventions
Blank control group:None
Metformin medium-dose group:Oral metformin 500mg twice daily
Metformin high-dose group:Oral metformin 500mg three times a day
Celecoxib group:Oral celecoxib 100mg twice daily
Sponsors
900th Hospital of PLA Joint Logistics Support Force
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. >=Patients aged 18 years who meet clinical diagnostic criteria for FAP; 2. One of the following is sufficient: (1) Patients with an intact colon with moderate adenomatous burden (100 to 1000 adenomatous polyps) and who are currently being considered for prophylactic surgery; (2) Surgical treatment has been performed, and the main surgical methods include subtotal colectomy + ileo-rectal anastomoses (IRA) and ileal-pouch-anal-anal-anal anastomosis (IPAA)
Exclusion criteria
Exclusion criteria: 1. Combined with other diseases that may affect the intestinal microbiota, such as inflammatory bowel disease, irritable bowel syndrome, and malabsorption caused by short bowel syndrome; 2. Immunosuppressants, glucocorticoids within 3 months prior to inclusion in the study; Have taken antibiotics, probiotics, prebiotics, etc. 1 month before the inclusion study; Have taken proton pump inhibitors, bismuth-containing medications, etc., within 2 weeks prior to inclusion in the study. 3. Diagnosis of malignant disease, such as CRC; 4. Use of non-steroidal anti-inflammatory drugs more than 3 times per week within 6 months prior to the trial; 5. Diagnosed with diabetes, pregnancy or breastfeeding; 6. Significant abnormalities in liver function and kidney function tests, or major infections, respiratory diseases, etc.; 7. Men trying to conceive; 8. Patients who are considered by the investigator to have factors that are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of polyps in the area of the descending colon marker;The size of the polyp in the marked area of the descending colon; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in Wnt signalling pathway-related indices of polyp cells before and after treatment;Polyp cell proliferation and apoptosis before and after treatment.; | — |
Countries
China
Contacts
Public ContactLi Dazhou
900th Hospital of PLA Joint Logistics Support Force
Outcome results
None listed